Insmed (0JAV) Share Forecast & Price Target

2 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0JAV Analyst Ratings

Strong Buy

19 Buy

0 Hold

0 Sell

Based on 19 analysts giving stock ratings to

Insmed

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0JAV Stock 12 Month Forecast

Average Price Target

$201.22

▲(69.75% Upside)

Based on 19 Wall Street analysts offering 12 month price targets for Insmed in the last 3 months. The average price target is $201.22 with a high forecast of $243.00 and a low forecast of $169.00. The average price target represents a 69.75% change from the last price of $118.54.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"97":"$97","244":"$244","133.75":"$133.8","170.5":"$170.5","207.25":"$207.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":243,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$243.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":201.22222222222223,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$201.22</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":169,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$169.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[97,133.75,170.5,207.25,244],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,98.11,109.25538461538461,120.40076923076923,131.54615384615386,142.69153846153847,153.83692307692309,164.9823076923077,176.1276923076923,187.27307692307693,198.41846153846154,209.56384615384616,220.70923076923077,231.85461538461539,{"y":243,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,98.11,106.0417094017094,113.97341880341881,121.90512820512821,129.8368376068376,137.76854700854702,145.70025641025643,153.6319658119658,161.56367521367522,169.49538461538464,177.42709401709402,185.3588034188034,193.29051282051284,{"y":201.22222222222223,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,98.11,103.56307692307692,109.01615384615384,114.46923076923076,119.9223076923077,125.3753846153846,130.82846153846154,136.28153846153845,141.73461538461538,147.18769230769232,152.64076923076922,158.09384615384616,163.54692307692306,{"y":169,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":107.67,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":135.24,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":147.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":189.12,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":210.94,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":174.2,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":154.016,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":146.72,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":165.19,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":135.13,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.089,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.73,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.11,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$243.00

Average Price Target$201.22

Lowest Price Target$169.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Leonid Timashev

RBC Capital

$195

Buy

64.50%

Upside

Reiterated

08/25/26

RBC Capital Reaffirms Their Buy Rating on Insmed (INSM)

Graig Suvannavejh

Mizuho Securities

$192→$195

Buy

64.50%

Upside

Reiterated

08/24/26

Insmed Earns Buy Rating as Brinsupri Japan Approval Drives Stronger Global Outlook and Price Target Raised to $195

Maxwell Skor

Morgan Stanley

$218

Buy

83.90%

Upside

Reiterated

08/24/26

Insmed: Japan Brinsupri Launch Underscores Long-Term Growth, Supports Unchanged $218 Price Target and Overweight Rating

Conor MacKay

BMO Capital

$192

Buy

61.97%

Upside

Reiterated

08/17/26

Analysts Are Bullish on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Insmed (INSM)

Andrew Fein

H.C. Wainwright

$220

Buy

85.59%

Upside

Reiterated

08/10/26

Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM), Minerva Neurosciences (NASDAQ: NERV) and Zymeworks (NASDAQ: ZYME)

Danielle Brill

Truist Financial

$185→$195

Buy

64.50%

Upside

Reiterated

08/10/26

Truist Financial Remains a Buy on Insmed (INSM)

Jessica Fye

J.P. Morgan

$179→$175

Buy

47.63%

Upside

Assigned

08/10/26

Insmed price target lowered to $175 from $179 at JPMorganInsmed price target lowered to $175 from $179 at JPMorgan

Gavin Clark-Gartner

Evercore ISI

$160→$170

Buy

43.41%

Upside

Reiterated

08/07/26

Insmed price target raised to $170 from $160 at Evercore ISIInsmed price target raised to $170 from $160 at Evercore ISI

Jason Zemansky

Bank of America Securities

$212→$214

Buy

80.53%

Upside

Reiterated

08/07/26

Bank of America Securities Keeps Their Buy Rating on Insmed (INSM)

Ashwani Verma

UBS

$166→$172

Buy

45.10%

Upside

Reiterated

08/07/26

Insmed price target raised to $172 from $166 at UBSInsmed price target raised to $172 from $166 at UBS

Adam Walsh

Roth MKM

$212

Buy

78.84%

Upside

Reiterated

08/07/26

Roth MKM Reaffirms Their Buy Rating on Insmed (INSM)

Eliana Merle

Barclays

$237

Buy

99.93%

Upside

Reiterated

08/07/26

Barclays Reaffirms Their Buy Rating on Insmed (INSM)

Ritu Baral

TD Cowen

$243

Buy

104.99%

Upside

Reiterated

08/06/26

Insmed (INSM): Brinsupri Outperformance and Raised Sales Guidance Support Buy Rating

Faisal Khurshid

Jefferies

$160→$175

Buy

47.63%

Upside

Reiterated

08/06/26

Insmed price target raised to $175 from $160 at JefferiesInsmed price target raised to $175 from $160 at Jefferies

Vamil Divan

Guggenheim

$207→$205

Buy

72.94%

Upside

Reiterated

08/06/26

Insmed price target lowered to $205 from $207 at GuggenheimInsmed price target lowered to $205 from $207 at Guggenheim

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Leonid Timashev

RBC Capital

$195

Buy

64.50%

Upside

Reiterated

08/25/26

RBC Capital Reaffirms Their Buy Rating on Insmed (INSM)

Graig Suvannavejh

Mizuho Securities

$192→$195

Buy

64.50%

Upside

Reiterated

08/24/26

Insmed Earns Buy Rating as Brinsupri Japan Approval Drives Stronger Global Outlook and Price Target Raised to $195

Maxwell Skor

Morgan Stanley

$218

Buy

83.90%

Upside

Reiterated

08/24/26

Insmed: Japan Brinsupri Launch Underscores Long-Term Growth, Supports Unchanged $218 Price Target and Overweight Rating

Conor MacKay

BMO Capital

$192

Buy

61.97%

Upside

Reiterated

08/17/26

Analysts Are Bullish on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Insmed (INSM)

Andrew Fein

H.C. Wainwright

$220

Buy

85.59%

Upside

Reiterated

08/10/26

Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM), Minerva Neurosciences (NASDAQ: NERV) and Zymeworks (NASDAQ: ZYME)

Danielle Brill

Truist Financial

$185→$195

Buy

64.50%

Upside

Reiterated

08/10/26

Truist Financial Remains a Buy on Insmed (INSM)

Jessica Fye

J.P. Morgan

$179→$175

Buy

47.63%

Upside

Assigned

08/10/26

Insmed price target lowered to $175 from $179 at JPMorganInsmed price target lowered to $175 from $179 at JPMorgan

Gavin Clark-Gartner

Evercore ISI

$160→$170

Buy

43.41%

Upside

Reiterated

08/07/26

Insmed price target raised to $170 from $160 at Evercore ISIInsmed price target raised to $170 from $160 at Evercore ISI

Jason Zemansky

Bank of America Securities

$212→$214

Buy

80.53%

Upside

Reiterated

08/07/26

Bank of America Securities Keeps Their Buy Rating on Insmed (INSM)

Ashwani Verma

UBS

$166→$172

Buy

45.10%

Upside

Reiterated

08/07/26

Insmed price target raised to $172 from $166 at UBSInsmed price target raised to $172 from $166 at UBS

Adam Walsh

Roth MKM

$212

Buy

78.84%

Upside

Reiterated

08/07/26

Roth MKM Reaffirms Their Buy Rating on Insmed (INSM)

Eliana Merle

Barclays

$237

Buy

99.93%

Upside

Reiterated

08/07/26

Barclays Reaffirms Their Buy Rating on Insmed (INSM)

Ritu Baral

TD Cowen

$243

Buy

104.99%

Upside

Reiterated

08/06/26

Insmed (INSM): Brinsupri Outperformance and Raised Sales Guidance Support Buy Rating

Faisal Khurshid

Jefferies

$160→$175

Buy

47.63%

Upside

Reiterated

08/06/26

Insmed price target raised to $175 from $160 at JefferiesInsmed price target raised to $175 from $160 at Jefferies

Vamil Divan

Guggenheim

$207→$205

Buy

72.94%

Upside

Reiterated

08/06/26

Insmed price target lowered to $205 from $207 at GuggenheimInsmed price target lowered to $205 from $207 at Guggenheim

Stocks with the Highest Top Analyst Consensus in the General Sector

STDNStandard Nuclear

SKHYSK Hynix

ITGITG Inc. Class A

LIMENeutron Holdings, Inc.

EROCERock

Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Insmed

3 Months

Jessica FyeJ.P. Morgan

Success Rate

16/21 ratings generated profit

Average Return

+23.03%

Copying Jessica Fye's trades and holding each position for 3 Months would result in 76.19% of your transactions generating a profit, with an average return of +23.03% per trade.

1 Year

Joseph SchwartzLeerink Partners

Success Rate

19/20 ratings generated profit

Average Return

+89.07%

Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 95.00% of your transactions generating a profit, with an average return of +89.07% per trade.

2 Years

Joseph SchwartzLeerink Partners

Success Rate

19/20 ratings generated profit

Average Return

+185.50%

Copying Joseph Schwartz's trades and holding each position for 2 Years would result in 95.00% of your transactions generating a profit, with an average return of +185.50% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0JAV Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0JAV has received 60 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 0JAV average Analyst price target in the past 3 months is 201.22.

Each month's total comprises the sum of three months' worth of ratings.

0JAV Financial Forecast

0JAV Earnings Forecast

Next quarter’s earnings estimate for 0JAV is -$0.39 with a range of -$0.90 to $0.04. The previous quarter’s EPS was -$0.06. 0JAV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year 0JAV has Performed in-line its overall industry.

0JAV Sales Forecast

Next quarter’s sales forecast for 0JAV is $501.22M with a range of $457.00M to $524.08M. The previous quarter’s sales results were $425.49M. 0JAV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year 0JAV has Performed in-line its overall industry.

0JAV Stock Forecast FAQ

What is GB:0JAV’s average 12-month price target, according to analysts?

Based on analyst ratings, Insmed’s 12-month average price target is 201.22.

What is GB:0JAV’s upside potential, based on the analysts’ average price target?

Insmed has 69.75% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Insmed a Buy, Sell or Hold?

Insmed has a consensus rating of Strong Buy, which is based on 19 buy ratings, 0 hold ratings and 0 sell ratings.

What is Insmed’s share price target?

The average share price target for Insmed is 201.22. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $243.00 ,and the lowest forecast is $169.00. The average share price target represents 69.75% Increase from the current price of $118.54.

What do analysts say about Insmed?

Insmed’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of Insmed?

To buy shares of GB:0JAV, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Insmed (0JAV) Share Forecast & Price Target

0JAV Analyst Ratings

0JAV Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Insmed

0JAV Analyst Recommendation Trends

0JAV Financial Forecast

0JAV Earnings Forecast

0JAV Sales Forecast

0JAV Stock Forecast FAQ

Detailed List of Analyst Forecasts